<- Go Home
Mirna Therapeutics, Inc.
As of August 28, 2017, Mirna Therapeutics, Inc was acquired by Synlogic, Inc in a reverse merger transaction. Mirna Therapeutics, Inc. does not have significant operations. It intends to identify and evaluate strategic alternatives, including a merger or sale of the company. Previously, the company was engaged in the development of microRNA-based oncology therapeutics. The company was founded in 2007 and is headquartered in Austin, Texas.
Market Cap
$38.1M
Volume
11.3K
Cash and Equivalents
$15.2M
EBITDA
-$20.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$18.34
52 Week Low
$7.84
Dividend
N/A
Price / Book Value
0.82
Price / Earnings
-1.34
Price / Tangible Book Value
0.82
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$20.4M
Return on Equity
47.28%
Return on Assets
-20.33
Cash and Short Term Investments
$47.7M
Debt
N/A
Equity
$46.7M
Revenue
N/A
Unlevered FCF
-$13.9M
Sector
Biotechnology
Category
N/A